Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach

Project description

Tumour hypoxia: friend or foe?

Low availability and uneven distribution of oxygen in the tumour microenvironment creates regions of hypoxia. Hypoxic conditions can promote cancer cell survival, genetic instability, and resistance to apoptosis, hampering the effectiveness of various treatments at the same time. Funded by the European Innovation Council, the TUMAGNOSTIC project aims to exploit hypoxia as a therapeutic target and promote a hypoxia-activated prodrug (HAP) called CP-506 for cancer treatment. This new approach integrates AI-driven biomarkers to increase the effectiveness of HAPs and improve clinical outcomes. Importantly, it can be used in conjunction with other types of therapies such as immunotherapy for improved efficacy.

Objective

TUMAGOSTIC will advance the development of CP-506, a next-generation Hypoxia Activated Prodrug (HAP) for the treatment of hypoxic tumours, representing over 50% of all solid tumours. CP-506 overcomes the limitations of previous HAP development attempts and can provide more targeted treatment compared with alternatives such as chemo-immunotherapy combination and PARPi. Our approach, combining CP-506 with improved patient targeting based on two AI-driven biomarkers (tumour hypoxia and Homologous Recombination Defect), has high potential to increase the effectiveness of standard of care therapies such as immunotherapy (IO) in combination therapy (prodrug-IO) and improve patients’ progression free survival and quality of life in several cancer types. We aim to advance CP-506 towards commercialization by carrying out a phase I-IIa clinical trial and corresponding business development activities, paving the way for a licensing agreement with the potential to exceed €450M.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

CONVERT PHARMACEUTICALS
Net EU contribution
€ 2 462 533,50
Address
Esplanade Simone Veil 1
4000 LIEGE
Belgium
SME
Yes
Region
Région wallonne Prov. Liège Arr. Liège
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 517 905,00